Diabetes drug metformin could slow blindness in rare eye disease
NCT ID NCT04545736
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests whether the diabetes drug metformin is safe and can slow vision loss in people with ABCA4 retinopathy (Stargardt disease), a genetic condition that causes progressive blindness. About 56 participants aged 12 and older will take metformin daily for 24 months, with regular eye exams to measure changes. The goal is to see if metformin can reduce the rate of retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109-0624, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.